ClinicalTrials.gg
CompletedNCT00557336Updated Feb 28, 2017

Efficacy and Safety of Growth Hormone Treatment in Children Small for Gestational Age

A Phase 3 interventional study of somatropin in Foetal Growth Problem and Small for Gestational Age, sponsored by Novo Nordisk A/S. Completed at 37 sites in Spain. Open to participants aged 2 Years to 14 Years. Per ClinicalTrials.gov, last updated 2017-02-28.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 years 3 months after the study started (first participant enrolled Jul 2003, registered Nov 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Non-randomized
Ages
2 Years to 14 Years
Sex
All
01

Study summary

This trial is conducted in Europe. The aim of this clinical trial is to evaluate the height gain during 12 months of growth hormone treatment in children born small for gestational age due to intrauterine growth retardation.

02

Conditions studied

  • Foetal Growth Problem
  • Small for Gestational Age
03

In context

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Born small for gestational age (SGA) due to intrauterine growth retardation (IUGR) defined as birth length and/or weight below P10
  • Chronological age at least 4 years old until bone age maturation of maximum 12 years for girls and maximum 13,5 for boys at time of inclusion in the study
  • Insufficient catch-up growth (height lesser than or equal to -2.5 SDS for chronological age
  • Normal response to GH stimulation test (greater than 10 ng/mL)

Exclusion criteria

Exclusion Criteria:

  • Diabetes
  • Growth retardation associated with infections severe chronic diseases (including chromosomal anomaly or nutritional disorders)
  • Treatment with any medical product (anabolic drugs, sex , etc.) which may interfere with GH effects
  • History or presence of severe disease that could interfere with GH treatment/participation in the trial, e.g. active
  • Previous or ongoing growth hormone therapy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
160 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Height gain according to birth group, age of onset, the treatment and Tanner stage

    Time frame: during 12 months of treatment

Secondary outcomes

  1. Height SDS for bone age

    Time frame: during 12 months of treatment

  2. Height velocity SDS for bone age

    Time frame: during 12 months of treatment

  3. Height velocity for chronological age

    Time frame: during 12 months of treatment

07

Study locations

37 sites
  • Novo Nordisk Investigational Site
    Albacete, 02006, Spain
  • Novo Nordisk Investigational Site
    Alicante, 03010, Spain
  • Novo Nordisk Investigational Site
    Almería, 04009, Spain
  • Novo Nordisk Investigational Site
    Badajoz, 06080, Spain
  • Novo Nordisk Investigational Site
    Badalona, 08916, Spain
  • Novo Nordisk Investigational Site
    Barcelona, 08009, Spain
  • Novo Nordisk Investigational Site
    Barcelona, 08025, Spain
  • Novo Nordisk Investigational Site
    Calella de la Costa, 08370, Spain
  • Novo Nordisk Investigational Site
    Cáceres, 10002, Spain
  • Novo Nordisk Investigational Site
    Córdoba, 14004, Spain
  • Novo Nordisk Investigational Site
    El Palmar, 30120, Spain
  • Novo Nordisk Investigational Site
    Elche, 3203, Spain
  • Novo Nordisk Investigational Site
    Esplugues Llobregat, 08950, Spain
  • Novo Nordisk Investigational Site
    Getafe, 28905, Spain
  • Novo Nordisk Investigational Site
    Granada, 18012, Spain
  • Novo Nordisk Investigational Site
    Granollers, 08400, Spain
  • Novo Nordisk Investigational Site
    Huelva, 21005, Spain
  • Novo Nordisk Investigational Site
    Jaén, 23007, Spain
  • Novo Nordisk Investigational Site
    Las Palmas, 35016, Spain
  • Novo Nordisk Investigational Site
    Leganés, 28911, Spain
  • Novo Nordisk Investigational Site
    Madrid, 28007, Spain
  • Novo Nordisk Investigational Site
    Madrid, 28009, Spain
  • Novo Nordisk Investigational Site
    Madrid, 28041, Spain
  • Novo Nordisk Investigational Site
    Madrid, 28046, Spain
  • Novo Nordisk Investigational Site
    Martorell, 08760, Spain
  • Novo Nordisk Investigational Site
    Mataró, 08304, Spain
  • Novo Nordisk Investigational Site
    Málaga, 29011, Spain
  • Novo Nordisk Investigational Site
    Palma de Mallorca, 07014, Spain
  • Novo Nordisk Investigational Site
    Pamplona, 31008, Spain
  • Novo Nordisk Investigational Site
    Sabadell, 08208, Spain
  • Novo Nordisk Investigational Site
    Salamanca, 37007, Spain
  • Novo Nordisk Investigational Site
    Santa Cruz de Tenerife, 38010, Spain
  • Novo Nordisk Investigational Site
    Santander, 39008, Spain
  • Novo Nordisk Investigational Site
    Sevilla, 41014, Spain
  • Novo Nordisk Investigational Site
    Tarrasa, 08227, Spain
  • Novo Nordisk Investigational Site
    Vitoria, 01009, Spain
  • Novo Nordisk Investigational Site
    Zaragoza, 50009, Spain
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2003 to primary completion in Jun 2005, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2007
First posted
Nov 14, 2007
StartActual
Jul 28, 2003
Primary completionActual
Jun 29, 2005
CompletionActual
Jun 29, 2005
Last update
Feb 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00557336
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Nov 14, 2007
Start date
Jul 28, 2003
Primary completion
Jun 29, 2005
Completion
Jun 29, 2005
Last update
Feb 28, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion